Direct Answer
Johnson & Johnson reports revenue across 2 business segments in its fiscal 2025 Form 10-K. Innovative Medicine is the largest, with $60.4 billion of revenue (64% of the total), followed by Med Tech at $33.8 billion (36%). 57% of revenue came from the United States.
How Does Johnson & Johnson Make Money?
Innovative Medicine supplies 64% of revenue, so Johnson & Johnson's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, Med Tech grew fastest (+6.1%) and Innovative Medicine slowest (+6.0%), so the revenue mix tilts toward Med Tech while that gap lasts.
| Segment | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| Innovative Medicine | $60.4 billion | $57.0 billion | 64.1% | 6.0% |
| Med Tech | $33.8 billion | $31.9 billion | 35.9% | 6.1% |
Where Does Johnson & Johnson's Revenue Come From?
Regions follow the definitions in the filing; most companies assign revenue by customer location.
| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| United States | $53.8 billion | $50.3 billion | 57.1% | 6.9% |
| Europe | $21.5 billion | $20.2 billion | 22.9% | 6.5% |
| Asia Pacific Africa | $14.0 billion | $13.6 billion | 14.9% | 3.2% |
| Western Hemisphere Excluding US | $4.9 billion | $4.7 billion | 5.2% | 3.4% |
What the Segment Figures Do Not Show
The rows above add up to 100% of Johnson & Johnson's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.
Where These Numbers Come From
Every figure on this page is a value Johnson & Johnson reported in the segment note and revenue disclosures of its Form 10-K filed February 11, 2026 (accession 0000200406-26-000016), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.
Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.
Frequently Asked Questions
What are Johnson & Johnson's business segments?
In its fiscal 2025 Form 10-K, Johnson & Johnson reports revenue for Innovative Medicine and Med Tech.
Which part of Johnson & Johnson brings in the most revenue?
Innovative Medicine, with $60.4 billion of revenue in fiscal 2025, or 64% of the total.
How much of Johnson & Johnson's revenue comes from outside the United States?
43% in fiscal 2025, by the geographic breakdown Johnson & Johnson reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.